Details of Host Protein-DME Interaction (HOSPPI)

General Information of Drug-Metabolizing Enzyme (DME ID: DME1422)
DME Name Molybdopterin-dependent enzyme (molD), Escherichia coli DME Info
UniProt ID
A0A327UAE0_9ACTN
EC Number    EC: 1.1.1.40     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
CH-OH donor oxidoreductase
NAD/NADP oxidoreductase
EC: 1.1.1.40
Lineage    Species: Escherichia coli     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Escherichia
Species: Escherichia coli
Subspecies: Escherichia coli BW25113
Interactome
Disease Specific Interactions between Host Protein and DME (HOSPPI)
      Drug co-metabolism
               Cometabolized drug: Doxorubicin Click to Show/Hide the Full List of HOSPPI:      16 HOSPPI
                            Aldo-keto reductase 1A1 (AKR1A1) Click to Show/Hide the Cometabolization Info
DME ID DME0098 DME Info
Uniprot ID
AK1A1_HUMAN
Interaction Name AKR1A1-molD interaction [1], [2]
Description The interaction, between human Aldo-keto reductase 1A1 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Aldo-keto reductase 1C3 (AKR1C3) Click to Show/Hide the Cometabolization Info
DME ID DME0118 DME Info
Uniprot ID
AK1C3_HUMAN
Interaction Name AKR1C3-molD interaction [1], [3]
Description The interaction, between human Aldo-keto reductase 1C3 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 2D6 (CYP2D6) Click to Show/Hide the Cometabolization Info
DME ID DME0009 DME Info
Uniprot ID
CP2D6_HUMAN
Interaction Name CYP2D6-molD interaction [1], [4]
Description The interaction, between human Cytochrome P450 2D6 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A4 (CYP3A4) Click to Show/Hide the Cometabolization Info
DME ID DME0001 DME Info
Uniprot ID
CP3A4_HUMAN
Interaction Name CYP3A4-molD interaction [1], [5]
Description The interaction, between human Cytochrome P450 3A4 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A5 (CYP3A5) Click to Show/Hide the Cometabolization Info
DME ID DME0012 DME Info
Uniprot ID
CP3A5_HUMAN
Interaction Name CYP3A5-molD interaction [1], [6]
Description The interaction, between human Cytochrome P450 3A5 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Methionine synthase reductase (MTRR) Click to Show/Hide the Cometabolization Info
DME ID DME0431 DME Info
Uniprot ID
MTRR_HUMAN
Interaction Name MTRR-molD interaction [1], [7]
Description The interaction, between human Methionine synthase reductase and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7) Click to Show/Hide the Cometabolization Info
DME ID DME0121 DME Info
Uniprot ID
NDUS7_HUMAN
Interaction Name NDUFS7-molD interaction [1], [8]
Description The interaction, between human NADH-ubiquinone oxidoreductase 20 kDa and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3) Click to Show/Hide the Cometabolization Info
DME ID DME0120 DME Info
Uniprot ID
NDUS3_HUMAN
Interaction Name NDUFS3-molD interaction [1], [8]
Description The interaction, between human NADH-ubiquinone oxidoreductase 30 kDa and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2) Click to Show/Hide the Cometabolization Info
DME ID DME0119 DME Info
Uniprot ID
NDUS2_HUMAN
Interaction Name NDUFS2-molD interaction [1], [8]
Description The interaction, between human NADH-ubiquinone oxidoreductase 49 kDa and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            NADPH-cytochrome P450 reductase (CPR) Click to Show/Hide the Cometabolization Info
DME ID DME0076 DME Info
Uniprot ID
NCPR_HUMAN
Interaction Name CPR-molD interaction [1], [9]
Description The interaction, between human NADPH-cytochrome P450 reductase and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Nitric oxide synthase brain (NOS1) Click to Show/Hide the Cometabolization Info
DME ID DME0122 DME Info
Uniprot ID
NOS1_HUMAN
Interaction Name NOS1-molD interaction [1], [10]
Description The interaction, between human Nitric oxide synthase brain and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Nitric oxide synthase endothelial (NOS3) Click to Show/Hide the Cometabolization Info
DME ID DME0123 DME Info
Uniprot ID
NOS3_HUMAN
Interaction Name NOS3-molD interaction [1], [10]
Description The interaction, between human Nitric oxide synthase endothelial and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Nitric oxide synthase inducible (NOS2) Click to Show/Hide the Cometabolization Info
DME ID DME0124 DME Info
Uniprot ID
NOS2_HUMAN
Interaction Name NOS2-molD interaction [1], [10]
Description The interaction, between human Nitric oxide synthase inducible and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Quinone reductase 1 (NQO1) Click to Show/Hide the Cometabolization Info
DME ID DME0097 DME Info
Uniprot ID
NQO1_HUMAN
Interaction Name NQO1-molD interaction [1], [8]
Description The interaction, between human Quinone reductase 1 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Succinic semialdehyde reductase (AKR7A2) Click to Show/Hide the Cometabolization Info
DME ID DME0234 DME Info
Uniprot ID
ARK72_HUMAN
Interaction Name AKR7A2-molD interaction [1], [11]
Description The interaction, between human Succinic semialdehyde reductase and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Xanthine dehydrogenase/oxidase (XDH) Click to Show/Hide the Cometabolization Info
DME ID DME0070 DME Info
Uniprot ID
XDH_HUMAN
Interaction Name XDH-molD interaction [1], [12]
Description The interaction, between human Xanthine dehydrogenase/oxidase and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
References
1 Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
2 Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
3 Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
4 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
5 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
6 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
7 Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
8 Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
9 Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
10 The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
11 Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010 Dec;335(3):533-45.
12 Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme. Curr Med Chem. 2016;23(35):4027-4036.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.